Status:
COMPLETED
Acetazolamide Challenge With Perfusion in the Prediction of Cerebral Vasospasm
Lead Sponsor:
University of Wisconsin, Madison
Conditions:
Subarachnoid Hemorrhage, Aneurysmal
Vasospasm, Cerebral
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The investigators propose a technique using cone beam CT perfusion (CBCTP) imaging with an acetazolamide challenge as a potential diagnostic tool to detect a defect in cerebral autoregulation at a tim...
Detailed Description
Acetazolamide or vasodilatory challenge should identify subjects having a abnormal cerebrovascular reactivity capacity. More specifically, after receiving the drug there will not be the expected incre...
Eligibility Criteria
Inclusion
- Patients with aneurysmal subarachnoid hemorrhage presenting to our institution within 24 hours of symptom onset
- Adults, 18 years of age or older
- Women of childbearing potential must not be pregnant (negative urine pregnancy test)
Exclusion
- Contraindication to acetazolamide (i.e. sulfonamide allergy, renal or liver failure)
- Contraindication to contrast media (Allergy or abnormal serum Cr and/or GFR based on current UW guidelines for IV contrast)
- Renal insufficiency, history of renal failure or renal transplant
- Hunt and Hess grade 1 and 5 (Attached protocol provides details on the grading scale. Grade 1 have lowest yield for vasospasm and Grade 5 are by definition critically ill and unstable patients)
- Critically ill patients who are unstable and who cannot undergo scans within the proposed timeline i.e. within 24 hours of the onset of their symptoms.
Key Trial Info
Start Date :
July 28 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 15 2022
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT03377049
Start Date
July 28 2019
End Date
July 15 2022
Last Update
July 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Wisconsin
Madison, Wisconsin, United States, 53792